Literature DB >> 6646989

Allosteric properties of the oxyphenbutazone--human serum albumin complex.

J H Dröge, L H Janssen, J Wilting.   

Abstract

The conformational change of albumin which occurs around physiological pH, the so-called N-B transition, has been studied by measuring the induced circular dichroic signal of the oxyphenbutazone-albumin complex. This N-B transition has been characterized by a set of parameters according to the two-state model of Monod, Wyman and Changeux. The influence of calcium ions on the N-B transition has been interpreted in terms of a change in some of the parameters describing the two-state model, viz. a decrease of the apparent pK value of the histidines and of the apparent allosteric constant of the oxyphenbutazone-albumin complex. This apparent pK change increases with increasing Ca2+ concentration, whereas the apparent allosteric constant approaches a final value at 5 mM Ca2+. From acid-base titration curves of albumin in the presence and in the absence of Ca2+ it could be concluded that in the presence of Ca2+ less histidines are titratable than in the absence of Ca2+. Assuming that these histidines are not involved in the N-B transition it follows that at least four to five histidines are involved in the N-B transition.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6646989     DOI: 10.1007/BF02332949

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  29 in total

1.  A structural transformation in bovine and human plasma albumins in alkaline solution as revealed by rotatory dispersion studies.

Authors:  W J LEONARD; K K VIJAI; J F FOSTER
Journal:  J Biol Chem       Date:  1963-06       Impact factor: 5.157

Review 2.  Overview of drug-protein binding.

Authors:  J R Gillette
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

Review 3.  Determinants of the response to oral anticoagulant drugs in man.

Authors:  R A O'Reilly; P M Aggeler
Journal:  Pharmacol Rev       Date:  1970-03       Impact factor: 25.468

4.  pK change of imidazole groups in bovine serum albumin due to the conformational change at neutral pH.

Authors:  B J Harmsen; S H De Bruin; L H Janssen; J F Rodrigues de Miranda; G A Van Os
Journal:  Biochemistry       Date:  1971-08-17       Impact factor: 3.162

5.  Consequences of the N-B transition of albumin for the binding of warfarin in human serum.

Authors:  W F van der Giesen; J Wilting
Journal:  Biochem Pharmacol       Date:  1983-01-15       Impact factor: 5.858

6.  The role of albumin conformation in the binding of diazepam to human serum albumin.

Authors:  J Wilting; B J Hart; J J De Gier
Journal:  Biochim Biophys Acta       Date:  1980-12-16

7.  A comparative study of some physico-chemical properties of human serum albumin samples from different sources--II. The characteristics of the N-B transition and the binding behaviour with regard to warfarin and diazepam.

Authors:  J H Dröge; J Wilting; L H Janssen
Journal:  Biochem Pharmacol       Date:  1982-12-01       Impact factor: 5.858

8.  On the nature of allosteric transitions: implications of non-exclusive ligand binding.

Authors:  M M Rubin; J P Changeux
Journal:  J Mol Biol       Date:  1966-11-14       Impact factor: 5.469

9.  A comparative study of some physico-chemical properties of human serum albumin samples from different sources--I. Some physico-chemical properties of isoionic human serum albumin solutions.

Authors:  J H Dröge; L H Janssen; J Wilting
Journal:  Biochem Pharmacol       Date:  1982-12-01       Impact factor: 5.858

10.  The effects of oleic acid, tolbutamide, and oxyphenbutazone on the binding of warfarin by human serum albumin.

Authors:  W D Wosilait; M P Ryan
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-09
View more
  1 in total

1.  The fatty-acid-induced conformational states of human serum albumin investigated by means of multiple co-binding of protons and oleic acid.

Authors:  J H Dröge; L H Janssen; J Wilting
Journal:  Biochem J       Date:  1988-03-01       Impact factor: 3.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.